Therapeutic bacteria and viruses to combat cancer: double-edged sword in cancer therapy: new insights for future
- PMID: 38654309
- PMCID: PMC11040964
- DOI: 10.1186/s12964-024-01622-w
Therapeutic bacteria and viruses to combat cancer: double-edged sword in cancer therapy: new insights for future
Abstract
Cancer, ranked as the second leading cause of mortality worldwide, leads to the death of approximately seven million people annually, establishing itself as one of the most significant health challenges globally. The discovery and identification of new anti-cancer drugs that kill or inactivate cancer cells without harming normal and healthy cells and reduce adverse effects on the immune system is a potential challenge in medicine and a fundamental goal in Many studies. Therapeutic bacteria and viruses have become a dual-faceted instrument in cancer therapy. They provide a promising avenue for cancer treatment, but at the same time, they also create significant obstacles and complications that contribute to cancer growth and development. This review article explores the role of bacteria and viruses in cancer treatment, examining their potential benefits and drawbacks. By amalgamating established knowledge and perspectives, this review offers an in-depth examination of the present research landscape within this domain and identifies avenues for future investigation.
Keywords: Bacteria; Cancer; Immunotherapy; Therapy; Viruses.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures
![Fig. 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11040964/bin/12964_2024_1622_Fig1_HTML.gif)
![Fig. 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11040964/bin/12964_2024_1622_Fig2_HTML.gif)
![Fig. 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11040964/bin/12964_2024_1622_Fig3_HTML.gif)
Similar articles
-
Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.Future Oncol. 2022 Jan;18(2):245-259. doi: 10.2217/fon-2021-0802. Epub 2021 Nov 25. Future Oncol. 2022. PMID: 34821517 Review.
-
Immuno-Oncolytic Viruses: Emerging Options in the Treatment of Colorectal Cancer.Mol Diagn Ther. 2021 May;25(3):301-313. doi: 10.1007/s40291-021-00517-7. Epub 2021 Mar 12. Mol Diagn Ther. 2021. PMID: 33713031 Review.
-
Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer.Front Immunol. 2018 Apr 26;9:866. doi: 10.3389/fimmu.2018.00866. eCollection 2018. Front Immunol. 2018. PMID: 29755464 Free PMC article. Review.
-
Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.Viruses. 2016 Jan 6;8(1):9. doi: 10.3390/v8010009. Viruses. 2016. PMID: 26751469 Free PMC article. Review.
-
Cancer and viruses: a double-edged sword.Proteomics. 2012 Jul;12(13):2127-38. doi: 10.1002/pmic.201100526. Proteomics. 2012. PMID: 22623378 Review.
References
-
- Baba AI, Câtoi C. Tumor cell morphology, in Comparative oncology. The Publishing House of the Romanian Academy; 2007. PMID: 20806453. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources